Catalyst Pharmaceuticals to Participate in Upcoming Investor Conferences

Core Insights - Catalyst Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company focused on developing and commercializing novel medicines for rare and difficult-to-treat diseases [1][3] - The company will participate in several upcoming investor conferences, including the Wells Fargo Healthcare Conference, H.C. Wainwright Global Investment Conference, and Cantor Global Healthcare Conference [2] Company Developments - Catalyst's flagship product, FIRDAPSE® (amifampridine) Tablets 10 mg, is approved for treating Lambert-Eaton myasthenic syndrome (LEMS) in patients aged 6 and older, with a recent FDA approval increasing the maximum daily dose to 100 mg for certain patients [3] - In January 2023, Catalyst acquired U.S. commercial rights to FYCOMPA® (perampanel), a medication for treating partial-onset seizures and primary generalized tonic-clonic seizures in patients aged 4 and older [4] - The company acquired an exclusive license for AGAMREE® (vamorolone), a treatment for Duchenne Muscular Dystrophy, which received FDA approval for commercialization in the U.S. on October 26, 2023, and became available by prescription on March 13, 2024 [5]